MTOR and breast carcinoma: The study has shown that metformin acts as a growth inhibitor in a dose-dependent manner by suppressing the mTOR/S6K pathway via LKB1–AMPK interaction in breast cancer cells, being the first to demonstrate its anticancer activity.